As we have shown that BCL-3 acts as a survival factor in the adenoma as well as carcinoma-derived cells, it is interesting to speculate that the ability to repress BCL-3 may contribute to the effectiveness of these NSAIDs in preventing tumorigenesis. The gene discussed is BCL3; the disease is carcinoma.